Successful administration of sequential TVEC and pembrolizumab followed by temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation by Khaddour, Karam et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
12-29-2020 
Successful administration of sequential TVEC and 
pembrolizumab followed by temozolomide in immunotherapy 







See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Karam Khaddour, Joshua Dowling, Jiayi Huang, Martha Council, David Chen, Lynn Cornelius, Tanner 
Johanns, Sonika Dahiya, and George Ansstas 
Oncotarget4836www.oncotarget.com
www.oncotarget.com Oncotarget, 2020, Vol. 11, (No. 52), pp: 4836-4844
Successful administration of sequential TVEC and pembrolizumab 
followed by Temozolomide in immunotherapy refractory 
intracranial metastatic melanoma with acquired B2M mutation
Karam Khaddour1, Joshua Dowling2, Jiayi Huang3, Martha Council4, David Chen4, 
Lynn Cornelius4, Tanner Johanns1, Sonika Dahiya5 and George Ansstas1
1Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA
2Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA 
3Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA 
4Division of Dermatology, Washington University School of Medicine, St. Louis, Missouri, USA 
5Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. 
Louis, Missouri, USA
Correspondence to: George Ansstas, email: Gansstas@wustl.edu
Keywords: metastatic melanoma; immune checkpoint inhibitor; temozolomide; acquired resistance; beta-2 microglobulin
Received: August 31, 2020 Accepted: December 08, 2020 Published: December 29, 2020
Copyright: © 2020 Khaddour et al. This is an open access article distributed under the terms of the Creative Commons Attribution License 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Despite the substantial advances in the management of metastatic melanoma 
with the introduction of immune checkpoint inhibitors (ICI), many patients develop 
disease progression during treatment with immunotherapy. This has been suggested to 
be mediated by several mechanisms that contribute to acquired resistance to ICI, one 
of which is acquired beta-2 microgloubulin (B2M) mutation. Talimogene laherparepvec 
(TVEC) is a genetically modified oncolytic virus that can enhance antitumor immunity. 
Temozolomide (TMZ) is an oral alkylating agent that has been suggested to augment 
anti-tumor immune response. The clinical significance of TVEC and TMZ in metastatic 
melanoma patients who are refractory to immunotherapy is unknown.  We report a 
case of a patient with immunotherapy refractory intracranial metastatic melanoma 
after initial response to ICI who had acquired B2M mutation. The patient received 
TVEC and pembrolizumab followed by TMZ. The patient maintained durable response 
of her visceral and intracranial disease for 19 months and ongoing. More research is 
essential to delineate whether TVEC or TMZ has efficacy in immunotherapy refractory 
metastatic melanoma with acquired B2M mutation.
INTRODUCTION
The development of immune checkpoint inhibitors 
(ICI) has transformed our management of metastatic 
malignancies and reshaped the field of oncology. 
ICIs are monoclonal antibodies that target checkpoint 
receptors present on tumor and immune cells in the tumor 
microenvironment. These medications unleash the anti-
tumor immune response by targeting checkpoint receptor 
proteins such as programmed death-1 (PD-1), programmed 
death ligand-1 (PD-L1) or cytotoxic associated lymphocyte 
antigen-4 (CTLA-4), among other receptors [1]. For 
metastatic melanoma, ICIs were approved after clinical 
trials demonstrated improved progression free survival 
(PFS) and overall survival (OS) over standard of care, 
and are now considered first line therapy. The long-term 
follow-up studies in patients with metastatic melanoma 
who were treated with ICI have further supported the 
durable responses achieved. The 5-year survival data with 
combined nivolumab (PD-1 inhibitor) and ipilimumab 
(CTLA-4 inhibitor) in the CheckMate 067 study has 
shown a median OS of more than 60 months in patients 
with metastatic melanoma [2]. Similarly, the 5-year follow 
up in the KEYNOTE-001 trial of patients with metastatic 
melanoma who were treated with pembrolizumab (PD-1 
inhibitor) showed a median OS of 38.6 months in treatment-
naïve patients [3]. Despite the remarkable results observed 
in multiple clinical trials, a significant number of patients 
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develop progressive disease during treatment [2, 3]. This has 
been suggested to be mediated by acquired resistance in the 
tumor microenvironment [4]. Of importance to this report, 
mutations in the beta-2-microglobulin (B2M), which is an 
essential component of MHC class I antigen presentation, 
have been suggested to confer acquired resistance to 
PD-1 inhibitors in metastatic melanoma [5]. Talimogene 
laherparepvec (TVEC) is a genetically modified oncolytic 
virus that has been suggested to restore tumor sensitivity to 
ICI and overcome resistance in immunotherapy refractory 
melanoma [6, 7]. Temozolomide (TMZ) which is an oral 
alkylating agent has demonstrated modest efficacy in the 
treatment of melanoma prior to the era of targeted therapy 
and ICI [8]. Interestingly, there is evidence of the modulating 
effect of TMZ on T-cell subsets which could alter the balance 
of the immune system but this has  not been well studied 
in melanoma [9]. Here, we report a case of a patient who 
presented with recurrent metastatic melanoma that initially 
responded to ICI but later progressed with identification 
of an acquired B2M mutation (loss of function) among 
other mutations that were detected. The patient was treated 
with TVEC and pembrolizumab followed by TMZ. The 
patient had complete durable remission for 19 months and 
ongoing. We discuss the possible role of TVEC and TMZ in 
immunotherapy resistant metastatic melanoma based on the 
available literature regarding their modulating effect of the 
immune system.
CASE PRESENTATION
A 33-year-old female presented due to stage IV 
recurrent metastatic melanoma to the bones, lung, liver and 
brain. Her medical history was significant for a diagnosis 
of melanoma in 2015 in the left arm (T3b) with ulceration 
and Breslow depth of 2.3 mm. She underwent wide local 
excision and sentinel lymph node biopsy with 2 positive 
axillary lymph nodes. This was followed by axillary lymph 
node dissection that showed 0 involved nodes out of 23 
total lymph nodes. The patient received high dose adjuvant 
interferon for 1 year. Surveillance computed tomography 
(CT) showed multiple liver, breast and lung lesions 
concerning for metastatic disease 8 months after concluding 
interferon therapy. Breast biopsy revealed metastatic 
melanoma and next-generation sequencing (NGS) showed 
NRAS (p.Q61H) mutation with variant allele fraction 
(VAF) of 77.4%, IDH1 (p.R132C) mutation with VAF 
of 52.4%, TERT promoter mutation and no alterations in 
BRAF, KIT, or B2M. RNA sequencing did not demonstrate 
overexpression of NRAS. At that time the patient 
commenced combination immunotherapy with ipilimumab 
(3 mg/kg) and nivolumab (1 mg/kg) intravenously every 
three weeks for 4 cycles. CT showed complete response 
and maintenance nivolumab was continued for 2 years 
complicated by mild vitiligo on the face during treatment. 
Six months after stopping maintenance nivolumab, she 
presented with the chief complaint of numerous rapidly 
progressing firm subcutaneous nodules in the back, 
right chest wall and bilateral axilla (Figure 1A). Positron 
Emission Tomography/Computed Tomography (PET/CT) 
with [18F] fluorodeoxyglucose (FDG) PET showed right 
apical chest wall osteolytic mass with intrapulmonary 
invasion, numerous subcutaneous metastatic nodules 
and nodular metastases involving the left breast, right 
adrenal gland, retroperitoneal and left perianal areas 
(Figure 1B). Brain magnetic resonance imaging (MRI) 
showed enhancing lesions in the left posterior parietal 
lobe measuring 2.4 × 2.1 × 1.8 cm, right parieto-occipital 
measuring 3.0 × 2.7 × 2.3 cm (Figure 2) as well as right 
inferior temporal lesion measuring 8 mm (not shown in 
the figures). The patient underwent gamma knife radiation 
to the metastatic brain lesions. Given disease recurrence 
and prior response to combination immune checkpoint 
inhibitors, she re-started ipilimumab (3 mg/kg) and 
nivolumab (1 mg/kg) intravenously every 4 weeks for 4 
cycles. The patient completed combination immunotherapy 
and developed grade 3 autoimmune hepatitis which was 
treated with glucocorticoids and mycophenolate mofetil. 
She subsequently developed new neurological symptoms 
presenting with headache and gait imbalance. Brain MRI 
showed progression in the right parietal lobe, right posterior 
cerebellum and the left posterior parietal lesions. She 
underwent resection of the symptomatic right parietal and 
right posterior fossa lesions and histopathology confirmed 
the diagnosis of metastatic melanoma (Figure 1C). This 
was followed by 30 Gy whole brain radiation over a total 
of 10 fractions. Repeat NGS analysis of a progressive lung 
lesion revealed the continued presence of a NRAS (p.Q61H) 
mutation with VAF of 49.6%, and IDH1 mutation (p.R132C) 
with VAF of 15.3% along with the interval development of 
a loss-of-function frameshift mutation in B2M with VAF 
of 14.5% (Figure 3A case report timeline). The presence 
of a B2M mutation was concerning for the development of 
acquired resistance to immunotherapy. We performed RNA 
sequencing which revealed overexpression of NRAS and 
tumor immune infiltrate composed of 27% immune cells 
in the tumor with T-cells constituting 44% (Figure 3B). 
Immunohistochemistry demonstrated PD-L1 expression of 
more than 30% in the tumor tissue (Figure 3B). 
Talimogene laherparepvec (TVEC) was started with 
pembrolizumab off-label due to refractory disease with 
visceral, cutaneous and brain metastases. The patient had 
good response of the subcutaneous nodules and visceral 
metastases but had continued radiographic progression 
of a left parietal lobe lesion which was associated 
with headache, nausea and vomiting and required left 
craniotomy with resection (Figure 2). Pathology of the 
brain showed reactive changes, hyalinized vessels, bland 
necrosis, and no evidence of malignancy (Figure 1D) 
most consistent with pseudoprogression.  After discussion 
with the patient, she commenced temozolomide (TMZ) 
at a dose of 150 mg/m2 daily for 5 days out of a 28-
day cycle. The patient experienced worsening of pre-
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existing immune-related vitiligo which manifested by 
hypopigmented macules and patches on the face, trunk and 
lower extremities after the 3rd cycle of TMZ (Figure 1E). 
Repeat PET-CT and brain MRI after 19 months of TMZ 
initiation showed no evidence of active disease. 
DISCUSSION
Despite the unprecedented advances in the treatment 
of metastatic melanoma with immune checkpoint 
inhibitors (ICI), there is a paucity of therapy options in 
patients with relapsed and refractory disease following 
progression during treatment with ICI. For example, 
the rate of progressive disease after initial response to 
ICI is estimated to be 64% at 5 years during treatment 
with ipilimumab-nivolumab combination and 79% with 
pembrolizumab [2, 3]. The development of progressive 
disease after initial response has been suggested 
to be mediated by acquired resistance in the tumor 
microenvironment [4]. This has created an unmet need 
for better understanding of resistance pathways leading to 
tumor escape from immune surveillance during treatment 
with ICI. Our report highlights an example of a patient who 
had a relapse with high burden and rapidly progressive 
intracranial and extracranial disease. She responded 
initially to ipilimumab-nivolumab followed by nivolumab 
maintenance but later had a recurrence of her disease 
and was re-challenged with combination ipilimumab-
nivolumab. Her visceral and intracranial disease continued 
to progress despite combination ICI and next-generation 
sequencing (NGS) revealed the presence of B2M mutation 
which we believe contributed to the acquired resistance 
to ICI [5]. Moreover, immunohistochemistry and RNA 
sequencing of the tumor tissue at progression after 
treatment with ipilimumab and nivolumab demonstrated 
an inflamed tumor tissue and abundance of tumor immune 
cell infiltrate (PD-L1 expression > 30% and immune cell 
infiltrate of 27% in the tumor, respectively). This however 
was associated with refractory disease to ICI. Of interest, 
the overexpression of NRAS in melanoma cells has 
been demonstrated to be associated with downregulation 
of MHC class I which consecutively can impair T-cell 
function in the tumor microenvironment and contribute 
to resistance to ICI [10–12]. Similarly, B2M mutation 
has been shown to interrupt MHC class I expression in 
the tumor microenvironment in melanoma and lead to 
acquired resistance to ICI [5]. One limitation in our case 
study is the inability to perform MHC class I expression 
in the tumor tissue due to unavailable detection methods 
at our institution. However, the presence of both B2M 
Figure 1: Recurrent metastatic melanoma. (A) Firm subcutaneous nodules in the axillary area and lateral chest wall. (B) 18F.
Fluorodeoxyglucose positron emission tomographic scan showing multiple metastatic lesions in the subcutaneous tissue, lung, breast, 
adrenal gland, pelvic and perianal area before start of ipilimumab-nivolumab (left). Persistent hypermetabolic metastatic lesions with 
increase in size an appearance of new lesions after 3 months of ipilimumab-nivolumab (center). Complete metabolic response one year after 
temozolomide (right). (C) Histopathology of metastatic brain lesions showing in the left malignant cells with an epithelioid appearance, 
harboring vesicular nuclei, and prominent nucleoli (H&E, 40X). In the right picture immunostain for HMB45 demonstrates strong diffuse 
cytoplasmic to paranuclear Golgi staining pattern in the tumor cells (B; 40X). (D) histopathology of another resected brain lesion showing 
reactive changes, hyalinized vessels, bland necrosis, and no evidence of malignancy Post TVEC and Pembrolizumab (consistent with 
pseudoprogression). (E) Hypo-pigmented macules and patches on the back, anterior chest wall and abdomen. 
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Figure 2: MRI of brain of metastatic lesions showing (A) coronal section demonstrating right parieto-occipital lesion at the start of 
ipilimumab-nivolumab (arrow). (B) coronal image showing right parieto-occipital and right cerebellar lesions (white arrows) and left 
posterior parietal lesion (blue arrow) after three cycles of ipilimumab-nivolumab. (C) Post-surgical resection of two symptomatic lesions- 
right parieto-occipital and right cerebellar lesions with persistent left posterior parietal lesion (arrow). (D) Enlarging left posterior parietal 
lesion post TVEC and pembrolizumab. (E) Surgical cavity after resection of left posterior parietal lesion and one month after TMZ 
treatment. (F) Collapsing surgical cavity of left posterior parietal lesion resection with no evidence of recurrent disease in the brain after 
19 months of temozolomide initiation. 
Figure 3: Timeline of the case and changes in lymphocyte count during treatment with temozolomide. (A) The timeline 
of the case report. (B) Demonstrates the evidence of an inflammatory tumor status at progression after treatment with ICI, to the left of the 
panel immunohistochemistry staining demonstrates PD-L1 expression > 30% and to the right RNA sequencing using Tempus xT identified 
tumor cell infiltration with immune cells composing 27% of the tumor infiltrate with predominance of T-cell infiltration constituting 44% 
of the infiltrate.
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mutation and NRAS overexpression has been shown 
as described previously to downregulate MCH class I 
expression which we believe contributed to the acquired 
resistance in our patient despite the abundance of immune 
cell infiltrate including T-cells (44% of the immune 
infiltrate). The patient had complete and durable response 
of her visceral metastatic disease after initiating TVEC 
and pembrolizumab followed by temozolomide (TMZ). 
The response observed after sequential administration 
of TVEC and pembrolizumab followed by TMZ raises 
several important points including the possible role of 
sequential use of TMZ after immunotherapy resistance 
due to its immunomodulatory effect  and the potential role 
of overcoming resistance to ICI with TVEC.
Immunotherapy and Temozolomide in 
metastatic melanoma
Preclinical and clinical data demonstrated a 
modulating effect of TMZ on the immune system leading 
to unleashed anti-tumor immune response. Several 
mechanisms have been proposed for resistance to ICI 
such as the interruption of tumor antigen presentation, 
inhibition of effector T-cell trafficking due to genetic 
and epigenetic alterations, imbalance between subset of 
effector and Treg cells and changes in signaling pathways 
mediated by cytokines [13–16]. Of importance, Treg cells 
have immunosuppressive effect on anti-tumor immunity 
and were found to have a role in the resistance to ICI 
leading to inadequate effector T-cell function against 
tumor cells [17]. Similarly, the depletion of Tregs have 
been suggested to restore effector T-cell function and 
lead to reactivation of anti-tumor immunity [17]. Another 
important mechanism of resistance in malignant melanoma 
involves the acquired mutations in the B2M gene leading 
to decreased expression of MHC class I molecules which 
are essential in antigen presentation and effective cytotoxic 
CD8 T-cell function against tumor cells [5].
TMZ is an oral alkylating agent that has shown 
modest efficacy and tolerability in patients with metastatic 
melanoma in the era preceding approval of targeted 
therapies and ICI [8]. In addition, TMZ has a negative 
effect on lymphocytes leading to lymphodepletion and 
can affect the number and function of Treg cells [18]. 
As such, Banissi et al. demonstrated that weight based 
low dose metronomic administration of temozolomide 
led to reduction in circulating Treg cells in rat glioma 
models [9]. Similarly, Ridolfi et al. showed a decrease 
in circulating Foxp3+ Treg cells after administration 
of daily temozolomide for 7 days which was further 
enhanced after the administration of autologous dendritic 
cell immunotherapy in patients with metastatic melanoma 
but this observation did not reflect improved clinical 
outcomes [19]. Whether the reduction of circulatory 
Treg cells correlates with a decrease in the number of 
Treg cells recruited in the tumor microenvironment has 
not been studied. However, the notion that TMZ can lead 
to a decrease in the number of Treg cells that have been 
suggested to contribute to the resistance to ICI points 
to a possible synergistic effect with ICI. The previous 
concept seems intriguing and has been documented in 
the literature when TMZ was used with immunotherapy 
including interleukin-2 (IL-2), dendritic cells (DC) 
autologous therapy and ICI such as PD-1 and CTLA-4 
inhibitors which is summarized in Table 1 [19–23]. The 
other mechanism by which TMZ is suggested to lead to 
immunomodulation in the tumor microenvironment is 
through the modulation of nuclear factor (NF)- kB which 
increases MHC class I expression in some tumor cells 
such as glioma [24]. 
Notably, sequential use of TMZ with ipilimumab 
in melanoma patients showed improved progression free 
survival rates at 6 months compared to ipilimumab alone 
which further support the previous notion [20]. Our patient 
had exacerbation of vitiligo which was a skin immune 
related adverse event (IRAEs), mainly at the sites of prior 
TVEC injections, three months after initiation of TMZ and 
despite being off ICI. This phenomenon is consistent with 
the observation that oncolytic adenovirus with TMZ can 
induce autophagy and antitumor immune responses [25]. 
In a similar report, Swami et al. demonstrated complete 
and durable remission with the use of metronomic TMZ 
in a patient with metastatic melanoma after refractory 
disease to pembrolizumab and the observed response 
was associated with the development of vitiligo [21]. In 
fact, development of vitiligo has been shown to correlate 
with improved response and prognosis in patients with 
metastatic melanoma treated with ICI [26]. As such, we 
believe that the exacerbation of skin IRAE in our patient 
during treatment with TMZ was associated with the 
maintained response. This raises a question on whether 
TMZ interaction with lymphocyte subsets could have 
led to induction of autoimmunity and restoration of anti-
tumor immune response. However, whether TMZ could 
overcome B2M mutation resistance requires further 
validation. Limitations to the hypothesis of a possible 
benefit of TMZ with immunotherapy in the reviewed 
studies include the small number of subjects included in 
these studies, different dosing and sequence of TMZ with 
immunotherapy that were used in investigations reported 
in the literature (summarized in Table 1) and lack of 
mechanistic insight on the role of Treg cells in the tumor 
microenvironment and mechanisms of resistance to ICI in 
metastatic melanoma.
TVEC and immunotherapy in metastatic 
melanoma
TVEC exerts its effect on injectable cutaneous 
melanoma sites and has been approved for unresectable 
and metastatic melanoma with small number of visceral 
metastases [27]. Also, TVEC has been suggested 
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to overcome resistance to ICI [28]. Despite many 
mechanisms of resistance that contribute to failure to 
ICI in metastatic melanoma, it is hypothesized that type 
I interferon pathway remains intact for many of these 
patients such as our patient who had no evidence of loss of 
downstream signaling through JAK1/2 gene modifications 
[28]. Hence, oncolytic viral injection of cancer cells can 
lead to upregulation of cytokines such as type I IFN 
which can activate natural killer cells. This can lead to the 
killing of target cells despite downregulated MHC class 
I expression due to mutations such as the loss of B2M, 
leading to restoration of anti-tumor immunity which 
could explain the systemic response observed in some 
the patients who receive TVEC. The activation of type 
I IFN pathway by oncolytic viral injection of malignant 
cells can explain the circumventing mechanism by which 
TVEC can bypass resistance to ICI and lead to restoration 
of anti-tumor immunity [29]. The response observed in 
our patient with regression of her cutaneous and visceral 
disease despite having acquired resistance to ICI could 
have been secondary to the administration of TVEC and 
pembrolizumab. Our patient’s intracranial and extracranial 
response to TVEC and pembrolizumab is similar to the 
report by Blake et al. [30] but our patient had more durable 
response which supports a possible role of adding TMZ in 
preventing further development of the metastatic disease.
Of interest, the patient had detectable isocitrate 
dehydrogenase (IDH) mutation which has been reported to 
be present with a frequency of 6% in malignant melanoma 
[31]. Interestingly, IDH mutated cancer cells are sensitive 
to TMZ but this has not been illustrated well in the case 
of melanoma [32]. The lack of evidence on the role of 
IDH mutations in tumurogenesis in metastatic melanoma 
and the effect of TMZ on IDH mutated melanoma cells 
poses intriguing questions on any possible interactions 
and benefit of using TMZ in patients with metastatic 
melanoma harboring IDH mutations.
Finally, it is important to highlight the limitation in 
our case study because of the inability to perform MHC 
class I expression at progression, which we believe was 
downregulated due to the presence of B2M mutation 
and NRAS overexpression. Moreover, it is difficult to 
Table 1: Studies of Temozolomide with immunotherapy in metastatic melanoma
Tumor Type 
(front line vs later line therapy)
Immunotherapy Dose of TMZ Sequence of Treatment Outcome References
Metastatic Melanoma
(Front line)
Ipilimumab 200 mg/m2 Induction: Ipi IV 10 mg/kg q3w + 
TMZ 200 mg/m2 days 1–4 q3w (4 
cycles)
Maintenance: Ipi 10 mg/kg q12w + 





PFS at 6 months 
45%
Patel SP,




Pembrolizumab 75 mg/m2 TMZ administered daily after 
progression on pembrolizumab 
for 6 weeks on, 2 weeks off until 
response*
Patient 1: Complete 
remission for 2 
years
Patient 2: Partial 
remission for 2 
months followed 
by PD
Patient 3: durable 
response for 8 
months before PD
Swami U,




HD IL-2 75 mg/m2 Patient who did not show response 
or progressed to HD IL-2 received 
TMZ for 3 weeks 
Rate of Complete 
or near complete 
response 67% (6 of 
9 patients) 
Fateh S,




HD IL-2 75 mg/m2 TMZ daily for three weeks followed 
by HD IL-12
No difference of 
ORR or durable 
response compared 
to single use of HD 
IL-2
Tarhini AA,





dendritic cells and 
IL-2
75 mg/m2 TMZ for 7-14 days prior to DC 
therapy and IL-2**





et al. 2013 
[19]
*Other treatments were administered to some patients including ipilimumab and CMP-001. **some patients in this study received CTLA-4 inhibitors. PD: 
progressive disease, TMZ: temozolomide, Ipi: ipilimumab, HD IL-2: High dose interleukin-2, mOS: median overall survival, mPFS: median progression 
free survival, ORR: overall response rate, DC: dendritic cell, Treg cells: T- regulatory cells. 
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conclude that the addition of TMZ had an added benefit to 
TVEC and pembrolizumab. However, TMZ has efficacy 
in intracranial tumors because of its ability to cross the 
blood-brain barrier which could have contributed to the 
response observed. In addition, development of vitiligo is 
known to be associated with a restored immune response 
in ICI treated melanoma patients, and this was observed 
in our patient after starting TMZ which we believe 
contributed to restoration of anti-tumor immune response. 
CONCLUSIONS
We report the first case to our knowledge of a 
successful administration of TVEC with pembrolizumab 
followed by TMZ in a patient with ICI refractory 
(intracranial and extracranial) metastatic melanoma with 
acquired B2M mutation.  This report highlights the need 
for further investigation on whether TVEC and TMZ have 
a role in immunotherapy refractory metastatic melanoma. 
This report should be interpreted with caution as more 
preclinical and clinical studies are essential to confirm 
whether the presence of acquired B2M mutation can 
be broken with the use of TVEC and pembrolizumab 
followed by TMZ. 
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